Analyses of melanoma patients treated with ipilimumab revealed that improved PFS and OS were associated with a low neutrophil‒lymphocyte ratio (NLR), low absolute neutrophil count, low frequency of myelogenous suppressor cells, low absolute monocyte count, high eosinophil count, high lymphocyte frequency and high frequency of forkhead box P3 (FoxP3) + Treg cells [8]. The gene discussed is FOXP3; the disease is melanoma.